NEFL and myeloid sarcoma: Serum neurofilament light chain (sNfL) is a promising biomarker of neuroaxonal injury in patients with MS, as it is closely correlated with relapsing activities, disability deterioration, brain shrinkage and therapy response (Barro et al., 2018; Kuhle et al., 2019; Kiani, 2023).